Ethical issues in contrast-enhanced magnetic resonance imaging screening for breast cancer

Topics in Magnetic Resonance Imaging

Volumn 13, Issue 2, 2002, Pages 79-84

  Plevritis, Sylvia K ^a   Ikeda, Debra M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Breast cancer; Breast MRI; Ethics; Informed consent; Mammography; Screening

Indexed keywords

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CONTRAST ENHANCEMENT; EARLY DIAGNOSIS; ETHICS; HEALTH CARE POLICY; INFORMED CONSENT; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

BREAST NEOPLASMS; CONTRAST MEDIA; ETHICS, MEDICAL; FEMALE; HUMANS; INFORMED CONSENT; MAGNETIC RESONANCE IMAGING; MASS SCREENING;

EID: 0036079191     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002142-200204000-00003     Document Type: Article

References (56)

1. The Edinburgh randomized trial of breast cancer screening: Results after 10 years of follow up
2. Mammographic screening and mortality from breast cancer: The Malmo mammographic screening trial
3. The Gothenburg Breast Cancer Screening Trial: Preliminary results on breast cancer mortality for women aged 39-49
4. Randomized study of mammography screening - Preliminary report on mortality in the Stockholm trial
5. Followup after 11 years - Update of mortality results in the Stockholm mammographic screening trial
6. The Canadian National Breast Screening Study: Update on breast cancer mortality
7. Breast cancer screening with mammography: Overview of Swedish randomized trials
8. Reduction in mortality from breast cancer after mass screening with mammography. Randomized trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare
9. Ten- to fourteen-year effect of screening on breast cancer mortality
10. Benefit of mammography screening in women ages 40 to 49 years. Current evidence from randomized controlled trials
11. Is screening for breast cancer with mammography justifiable?
12. Screening for breast cancer with mammography
13. Cochrane review on screening for breast cancer with mammography
14. MR imaging of the breast
15. MR imaging: Breast cancer staging and screening
16. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results
17. Application of magnetic resonance imaging to early detection of breast cancer
18. MR imaging of the breast: Fast imaging sequences with and without Gd-DTPA. Preliminary observations
19. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer
20. Breast disease: Dynamic spiral MR imaging
21. Dynamic high-spatialresolution MR imaging of suspicious breast lesions: Diagnostic criteria and interobserver variability
22. Characterization of breast lesion morphology with delayed 3DSSMT: An adjunct to dynamic breast MRI
23. Magnetic resonance imaging screening in women at genetic risk of breast cancer: Imaging and analysis protocol for the UK multicenter study
24. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer
25. Localization of breast lesions shown only on MRI - A review for the UK Study of MRI Screening for Breast Cancer
26. First experiences in screening women at high risk for breast cancer with MR imaging
27. Screening for disease
28. Pairing accountability with responsibility - The consequences of screening "promotion"
29. All-cause mortality in randomized trials of cancer screening
30. An overview of the breast cancer screening controversy
31. Application of magnetic resonance imaging to angiogenesis in breast cancer
32. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
33. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI
34. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis
35. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
36. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma
37. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: How much more breast cancer can we find?
38. False-negative MR imaging of malignant breast tumors
39. Ductal carcinoma in situ: MR imaging-histopathologic correlation
40. MR imaging of ductal carcinoma in situ
41. Quality of life assessment for cost/utility studies in cancer
42. Incidental enhancing lesions (IEL) detected during contrast-enhanced breast magnetic resonance (MR) imaging scans: Incidence and clinical impact
43. Serendipity in diagnostic imaging: Magnetic resonance imaging of the breast
44. Incidental enhancing lesions found on MR imaging of the breast
45. Quality of life following a false positive mammogram
46. Screening behavior of women after a false-positive mammogram
47. The management of ductal carcinoma in situ (DCIS)
48. Ductal carcinoma in situ of the breast
49. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies
50. Heterogeneity of ductal carcinoma in situ of the breast
51. Heterogeneity of intraductal carcinoma of the breast
52. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: Cross sectional survey
53. Use of 3 point Dixon MR imaging to guide 14 gauge core needle biopsy of breast lesions in an open 0.5T MRT system
54. Breast lesion localization: A freehand, interactive MR imaging-guided technique
55. Localization and biopsy of breast lesions by magnetic resonance imaging guidance